"As per expert advice, Kazia is already close to agreeing to a new DIPG study, where paxalisib will be the therapy core, with another drug(s) used to block a further pathway(s). we expect the company will make paxalisib’s future in DIPG clear once a trial has been formally agreed to with researchers."
Kazia Share Price, page-209
-
- There are more pages in this discussion • 583 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)